Iovance Biotherapeutics Inc

Latest Results (24.05.2026):

Iovance Biotherapeutics Inc reported strong fourth quarter 2025 results with product revenue of approximately $87 million (≈30% sequential growth) driven by Amtagvi, and full‑year 2025 product revenue of about $264 million (within guidance). The company improved gross margin to ~50%, reported a Q4 net loss of $71.9 million and a full‑year net loss of $391.0 million, and ended 2025 with cash and investments of roughly $303 million—projected to fund operations into the third quarter of 2027. Commercial momentum for Amtagvi and regulatory/clinical progress for lifileucel were also emphasized.

Revenue and growth

Q4 2025 product revenue was ~$87M (product revenue, net $86.8M), up ~30% sequentially; full‑year 2025 product revenue was ~$264M (net $263.5M), achieving the company’s $250–$300M guidance range. U.S. Amtagvi accounted for the majority (~$65M in Q4, ~$220M for FY25) with Proleukin contributing ~$22M in Q4 and ~$44M for the year.

Profitability & margins

Gross margin from cost of sales improved to ~50% in Q4 2025, reflecting operational execution and cost optimization initiatives that the company expects will further improve margins in 2026–2027.

Quarter and full‑year net loss

Net loss for Q4 2025 was $71.9M (loss per share $0.18); net loss for FY2025 was $391.0M (loss per share $1.09). Loss from operations was $73.5M in Q4 and $403.4M for the year.

Cash position and runway

Cash, cash equivalents and investments totaled about $297.0M (plus ~$6.0M restricted cash = ~$303M total) as of December 31, 2025; management expects these resources to fund operations into Q3 2027.

Operating costs

Q4 operating costs included cost of sales $43.1M, R&D $71.2M and SG&A $36.4M (total costs and expenses $160.2M). Management highlighted internalization of lifileucel manufacturing and R&D optimization to reduce expenses going forward.

Amtagvi commercial launch

Amtagvi uptake drove the revenue increase; the company reported strong real‑world ORRs (~44% overall, 52% after ≤2 prior lines in an ASTCT/CIBMTR presentation), expanded authorized treatment centers, introduction of a specialty‑pharmacy channel, and global regulatory activity including Canadian approval in Aug 2025 and pending reviews/submissions in multiple markets.

Regulatory & clinical momentum for lifileucel

The FDA granted Fast Track Designation for lifileucel in previously treated metastatic nonsquamous NSCLC; interim single‑dose data show a 26% ORR with mDOR not reached at 25+ months. Iovance plans to complete enrollment in 2026 and pursue a supplemental BLA with a potential U.S. launch in H2 2027.

Manufacturing & operational improvements

Manufacturing turnaround time improved to 32 days or less from inbound to return shipment to authorized treatment centers, and management plans further internalization and efficiency gains to lower cost of sales.

Pipeline progress

Positive early lifileucel data in advanced sarcomas (50% ORR in first evaluable patients) and progress across multiple Phase 1/2 and Phase 3 programs (including TILVANCE‑301 in frontline melanoma and other investigator‑sponsored trials) position the company to report additional data and submit new INDs/MAAs through 2026–2027.